Skip to main content

PMD Act — the Legal Definition

JP-unique

Japan's PMD Act combines pharmaceuticals, medical devices, and regenerative medicine products in a single statute. This structure has no direct parallel in EU MDR, FDA 510(k)/PMA, or TGA frameworks, which have separate legislation for each product type.

What the PMD Act is

The Pharmaceuticals and Medical Devices Act (医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律) — commonly abbreviated as the PMD Act — is Act No. 145 of 1960, as extensively amended. Its full title translates to "Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices."

The PMD Act governs:

  • Pharmaceuticals
  • Quasi-drugs
  • Cosmetics
  • Medical devices (including IVDs and SaMD)
  • Regenerative medicine products and cellular/gene therapy products

For medical devices, the PMD Act establishes the legal basis for classification, pre-market approval and certification, manufacturing and distribution licensing, post-market surveillance, adverse event reporting, recalls, and enforcement.

History and the 2014 rename

The law was originally enacted as the Pharmaceutical Affairs Law (PAL) (薬事法) in 1960. The 2014 amendments renamed it to the PMD Act and introduced major structural changes specifically for medical devices:

  • The three-pathway system (Shonin / Ninsho / Todokede) was established in its current form
  • A dedicated framework for regenerative medicine products was created
  • The Marketing Authorization Holder (MAH) concept was refined
  • A new framework for Programme Medical Devices (software as a medical device) was introduced

Prior to 2014, medical devices and pharmaceuticals used more similar regulatory pathways. The 2014 changes recognised the distinct nature of medical device regulation and moved it closer to international standards (particularly GHTF/IMDRF).

Key articles for medical device practitioners

ArticleSubject
Article 2(4)Definition of medical devices
Article 2(5)Definition of in vitro diagnostics
Article 13Manufacturing business licence (domestic)
Article 14Pre-market approval — Shonin
Article 23-2-5Pre-market certification — Ninsho
Article 23-2-12Pre-market notification — Todokede
Article 40-2Repair business requirements
Article 63Labelling obligations
Article 68-2Adverse event reporting
Article 69MHLW collection of adverse event information
Article 72Recalls and corrective actions
Article 80-8Foreign Manufacturer Registration

Where to find the current text

Note that English translations on the PMDA website may lag behind the most recent amendments. Always verify the Japanese text for the most current version before relying on the English translation for a regulatory decision.